Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Quantifying the setup uncertainty of a stereotactic murine micro-image guided radiation therapy system.

Walb MC, Carlson BL, Sarkaria JN, Tryggestad EJ.

Br J Radiol. 2018 Oct 9:20180487. doi: 10.1259/bjr.20180487. [Epub ahead of print]

PMID:
30299986
2.

Methylation-dependent Tissue Factor suppression contributes to the reduced malignancy of IDH1 mutant gliomas.

Unruh D, Mirkov S, Wray B, Drumm M, Lamano J, Li YD, Haider QF, Javier R, McCortney K, Saratsis AM, Scholtens DM, Sarkaria JN, James CD, Horbinski C.

Clin Cancer Res. 2018 Sep 28. pii: clincanres.1222.2018. doi: 10.1158/1078-0432.CCR-18-1222. [Epub ahead of print]

PMID:
30266764
3.

IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling.

Oliva CR, Halloran B, Hjelmeland AB, Vazquez A, Bailey SM, Sarkaria JN, Griguer CE.

Cell Commun Signal. 2018 Sep 19;16(1):61. doi: 10.1186/s12964-018-0273-7.

4.

ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.

Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, Harmsen WS, Yuan J, Boughey JC, Goetz MP, Sarkaria JN, Lou Z, Mutter RW.

Mol Cancer Ther. 2018 Aug 30. doi: 10.1158/1535-7163.MCT-18-0470. [Epub ahead of print]

PMID:
30166399
5.

Investigating Dependencies of Relative Biological Effectiveness for Proton Therapy in Cancer Cells.

Howard ME, Beltran C, Anderson S, Tseung WC, Sarkaria JN, Herman MG.

Int J Part Ther. 2018 Winter;4(3):12-22. doi: 10.14338/IJPT-17-00031.1. Epub 2018 Mar 21.

6.

Hypoxia-inducible factor 2α: a novel target in gliomas.

Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, Frenkel MB, Sarkaria JN, Lesser GJ, Strowd RE.

Future Med Chem. 2018 Sep 1;10(18):2227-2236. doi: 10.4155/fmc-2018-0163. Epub 2018 Aug 9.

PMID:
30089425
7.

A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine.

Jun HJ, Appleman VA, Wu HJ, Rose CM, Pineda JJ, Yeo AT, Delcuze B, Lee C, Gyuris A, Zhu H, Woolfenden S, Bronisz A, Nakano I, Chiocca EA, Bronson RT, Ligon KL, Sarkaria JN, Gygi SP, Michor F, Mitchison TJ, Charest A.

Nat Commun. 2018 Aug 6;9(1):3116. doi: 10.1038/s41467-018-05036-4.

8.

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma.

Chen X, Zhang M, Gan H, Wang H, Lee JH, Fang D, Kitange GJ, He L, Hu Z, Parney IF, Meyer FB, Giannini C, Sarkaria JN, Zhang Z.

Nat Commun. 2018 Jul 27;9(1):2949. doi: 10.1038/s41467-018-05373-4.

9.

Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.

Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF.

Pharm Res. 2018 Jul 12;35(9):177. doi: 10.1007/s11095-018-2455-9. Review.

PMID:
30003344
10.

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.

Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, Eckel-Passow JE, Kitange GJ, Johnson AJ, Parney IF, Anastasiadis PZ, Agar NYR, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2018 Sep;17(9):1893-1901. doi: 10.1158/1535-7163.MCT-17-0600. Epub 2018 Jul 3.

PMID:
29970480
11.

H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers.

Fang D, Gan H, Cheng L, Lee JH, Zhou H, Sarkaria JN, Daniels DJ, Zhang Z.

Elife. 2018 Jun 22;7. pii: e36696. doi: 10.7554/eLife.36696.

12.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, Weroha SJ, Jen J, Sarkaria JN, Galanis E.

J Natl Cancer Inst. 2018 Oct 1;110(10):1123-1132. doi: 10.1093/jnci/djy033.

PMID:
29788332
13.

Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.

Bristow RG, Alexander B, Baumann M, Bratman SV, Brown JM, Camphausen K, Choyke P, Citrin D, Contessa JN, Dicker A, Kirsch DG, Krause M, Le QT, Milosevic M, Morris ZS, Sarkaria JN, Sondel PM, Tran PT, Wilson GD, Willers H, Wong RKS, Harari PM.

Lancet Oncol. 2018 May;19(5):e240-e251. doi: 10.1016/S1470-2045(18)30096-2. Review.

PMID:
29726389
14.

Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.

Linninger A, Hartung GA, Liu BP, Mirkov S, Tangen K, Lukas RV, Unruh D, James CD, Sarkaria JN, Horbinski C.

Neuro Oncol. 2018 Aug 2;20(9):1197-1206. doi: 10.1093/neuonc/noy051.

PMID:
29660019
15.

Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues.

Zhou D, Alver BM, Li S, Hlady RA, Thompson JJ, Schroeder MA, Lee JH, Qiu J, Schwartz PH, Sarkaria JN, Robertson KD.

Genome Biol. 2018 Mar 27;19(1):43. doi: 10.1186/s13059-018-1420-6.

16.

Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition.

Herrera-Perez RM, Voytik-Harbin SL, Sarkaria JN, Pollok KE, Fishel ML, Rickus JL.

PLoS One. 2018 Mar 22;13(3):e0194183. doi: 10.1371/journal.pone.0194183. eCollection 2018.

17.

Molecular and Structural Traits of Insulin Receptor Substrate 1/LC3 Nuclear Structures and Their Role in Autophagy Control and Tumor Cell Survival.

Lassak A, Dean M, Wyczechowska D, Wilk A, Marrero L, Trillo-Tinoco J, Boulares AH, Sarkaria JN, Del Valle L, Peruzzi F, Ochoa A, Reiss K.

Mol Cell Biol. 2018 Apr 30;38(10). pii: e00608-17. doi: 10.1128/MCB.00608-17. Print 2018 May 15.

PMID:
29483302
18.

Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier.

Laramy JK, Kim M, Parrish KE, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2018 May;365(2):249-261. doi: 10.1124/jpet.117.246116. Epub 2018 Feb 12.

PMID:
29440450
19.

Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.

Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF.

Drug Metab Dispos. 2018 May;46(5):658-666. doi: 10.1124/dmd.117.079194. Epub 2018 Feb 2.

PMID:
29437873
20.

LPA signaling is regulated through the primary cilium: a novel target in glioblastoma.

Loskutov YV, Griffin CL, Marinak KM, Bobko A, Margaryan NV, Geldenhuys WJ, Sarkaria JN, Pugacheva EN.

Oncogene. 2018 Mar;37(11):1457-1471. doi: 10.1038/s41388-017-0049-3. Epub 2018 Jan 11.

21.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

Schiff D, Jaeckle KA, Anderson SK, Galanis E, Giannini C, Buckner JC, Stella P, Flynn PJ, Erickson BJ, Schwerkoske JF, Kaluza V, Twohy E, Dancey J, Wright J, Sarkaria JN.

Cancer. 2018 Apr 1;124(7):1455-1463. doi: 10.1002/cncr.31219. Epub 2018 Jan 3.

PMID:
29313954
22.

Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics.

Pedron S, Polishetty H, Pritchard AM, Mahadik BP, Sarkaria JN, Harley BAC.

MRS Commun. 2017 Sep;7(3):442-449. doi: 10.1557/mrc.2017.85. Epub 2017 Sep 12.

23.

Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.

Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, Dietrich PY, Weis SM, Mischel PS, Cheresh DA.

Cancer Cell. 2017 Dec 11;32(6):856-868.e5. doi: 10.1016/j.ccell.2017.10.016. Epub 2017 Nov 30.

PMID:
29198914
24.

Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF.

Neuro Oncol. 2018 Jan 22;20(2):184-191. doi: 10.1093/neuonc/nox175.

PMID:
29016900
25.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC.

Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

PMID:
29016887
26.

Real-Time Methylation-Specific Polymerase Chain Reaction for MGMT Promoter Methylation Clinical Testing in Glioblastoma: An Alternative Detection Method for a Heterogeneous Process.

Ida CM, Butz ML, Jenkins RB, Sarkaria JN, Kitange GJ, Giannini C, Kipp BR.

Am J Clin Pathol. 2017 Oct 1;148(4):296-307. doi: 10.1093/ajcp/aqx073.

PMID:
28967952
27.

Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.

Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2017 Dec;16(12):2735-2746. doi: 10.1158/1535-7163.MCT-17-0365. Epub 2017 Sep 25.

PMID:
28947502
28.

CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.

Avril T, Etcheverry A, Pineau R, Obacz J, Jegou G, Jouan F, Le Reste PJ, Hatami M, Colen RR, Carlson BL, Decker PA, Sarkaria JN, Vauléon E, Chiforeanu DC, Clavreul A, Mosser J, Chevet E, Quillien V.

Clin Cancer Res. 2017 Dec 1;23(23):7360-7374. doi: 10.1158/1078-0432.CCR-17-1549. Epub 2017 Sep 22.

29.

Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.

Müller-Greven G, Carlin CR, Burgett ME, Ahluwalia MS, Lauko A, Nowacki AS, Herting CJ, Qadan MA, Bredel M, Toms SA, Lathia JD, Hambardzumyan D, Sarkaria JN, Hamerlik P, Gladson CL.

Clin Cancer Res. 2017 Nov 15;23(22):7059-7071. doi: 10.1158/1078-0432.CCR-17-0249. Epub 2017 Sep 14.

PMID:
28912141
30.

Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.

Laramy JK, Kim M, Gupta SK, Parrish KE, Zhang S, Bakken KK, Carlson BL, Mladek AC, Ma DJ, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2017 Nov;363(2):136-147. doi: 10.1124/jpet.117.243477. Epub 2017 Aug 28.

PMID:
28847917
31.

Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma.

Pedron S, Hanselman JS, Schroeder MA, Sarkaria JN, Harley BAC.

Adv Healthc Mater. 2017 Nov;6(21). doi: 10.1002/adhm.201700529. Epub 2017 Aug 2.

PMID:
28766870
32.

Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF.

Pharmacol Res. 2017 Sep;123:10-25. doi: 10.1016/j.phrs.2017.06.008. Epub 2017 Jun 17.

33.

A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.

Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, Pan E, Mickey B, Burma S, Wang DH, Kesari S, Sarkaria JN, Zhao D, Habib AA.

Nat Neurosci. 2017 Aug;20(8):1074-1084. doi: 10.1038/nn.4584. Epub 2017 Jun 12.

34.

Challenges in the delivery of therapies to melanoma brain metastases.

Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN, Elmquist WF.

Curr Pharmacol Rep. 2016 Dec;2(6):309-325. doi: 10.1007/s40495-016-0072-z. Epub 2016 Nov 9.

35.

EGFR Signals through a DOCK180-MLK3 Axis to Drive Glioblastoma Cell Invasion.

Misek SA, Chen J, Schroeder L, Rattanasinchai C, Sample A, Sarkaria JN, Gallo KA.

Mol Cancer Res. 2017 Aug;15(8):1085-1095. doi: 10.1158/1541-7786.MCR-16-0318. Epub 2017 May 9.

36.

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.

McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.

Neuro Oncol. 2017 Oct 19;19(11):1469-1480. doi: 10.1093/neuonc/nox044.

37.

Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix.

Heim JB, Squirewell EJ, Neu A, Zocher G, Sominidi-Damodaran S, Wyles SP, Nikolova E, Behrendt N, Saunte DM, Lock-Andersen J, Gaonkar KS, Yan H, Sarkaria JN, Krendel M, van Deursen J, Sprangers R, Stehle T, Böttcher RT, Lee JH, Ordog T, Meves A.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3933-3938. doi: 10.1073/pnas.1614894114. Epub 2017 Mar 27.

38.

Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells.

Mamo T, Mladek AC, Shogren KL, Gustafson C, Gupta SK, Riester SM, Maran A, Galindo M, van Wijnen AJ, Sarkaria JN, Yaszemski MJ.

Biochem Biophys Res Commun. 2017 Apr 29;486(2):307-313. doi: 10.1016/j.bbrc.2017.03.033. Epub 2017 Mar 12.

39.

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.

Tivnan A, Heilinger T, Ramsey JM, O'Connor G, Pokorny JL, Sarkaria JN, Stringer BW, Day BW, Boyd AW, Kim EL, Lode HN, Cryan SA, Prehn JH.

Oncotarget. 2017 Mar 7;8(10):16605-16620. doi: 10.18632/oncotarget.15073.

40.

Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways.

Bijangi-Vishehsaraei K, Reza Saadatzadeh M, Wang H, Nguyen A, Kamocka MM, Cai W, Cohen-Gadol AA, Halum SL, Sarkaria JN, Pollok KE, Safa AR.

J Neurosurg. 2017 Dec;127(6):1219-1230. doi: 10.3171/2016.8.JNS161197. Epub 2017 Jan 6.

41.

DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.

Nagel ZD, Kitange GJ, Gupta SK, Joughin BA, Chaim IA, Mazzucato P, Lauffenburger DA, Sarkaria JN, Samson LD.

Cancer Res. 2017 Jan 1;77(1):198-206. doi: 10.1158/0008-5472.CAN-16-1151. Epub 2016 Oct 28.

42.

Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.

Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD.

Neuro Oncol. 2016 Nov;18(11):1519-1528. Epub 2016 Jul 1.

43.

Network Modeling Identifies Patient-specific Pathways in Glioblastoma.

Tuncbag N, Milani P, Pokorny JL, Johnson H, Sio TT, Dalin S, Iyekegbe DO, White FM, Sarkaria JN, Fraenkel E.

Sci Rep. 2016 Jun 29;6:28668. doi: 10.1038/srep28668.

44.

Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.

Lescarbeau RS, Lei L, Bakken KK, Sims PA, Sarkaria JN, Canoll P, White FM.

Mol Cancer Ther. 2016 Jun;15(6):1332-43. doi: 10.1158/1535-7163.MCT-15-0692. Epub 2016 May 17.

45.

Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.

Wang H, Cai S, Bailey BJ, Reza Saadatzadeh M, Ding J, Tonsing-Carter E, Georgiadis TM, Zachary Gunter T, Long EC, Minto RE, Gordon KR, Sen SE, Cai W, Eitel JA, Waning DL, Bringman LR, Wells CD, Murray ME, Sarkaria JN, Gelbert LM, Jones DR, Cohen-Gadol AA, Mayo LD, Shannon HE, Pollok KE.

J Neurosurg. 2017 Feb;126(2):446-459. doi: 10.3171/2016.1.JNS152513. Epub 2016 May 13.

46.

Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.

Kitange GJ, Mladek AC, Schroeder MA, Pokorny JC, Carlson BL, Zhang Y, Nair AA, Lee JH, Yan H, Decker PA, Zhang Z, Sarkaria JN.

Cell Rep. 2016 Mar 22;14(11):2587-98. doi: 10.1016/j.celrep.2016.02.045. Epub 2016 Mar 10.

47.

SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.

Ensign SP, Roos A, Mathews IT, Dhruv HD, Tuncali S, Sarkaria JN, Symons MH, Loftus JC, Berens ME, Tran NL.

Mol Cancer Res. 2016 Mar;14(3):302-12. doi: 10.1158/1541-7786.MCR-15-0183. Epub 2016 Jan 13.

48.

Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, Eckel-Passow JE, Sarkar G, Ballman KV, Reid JM, Jenkins RB, Verhaak RG, Sulman EP, Kitange GJ, Sarkaria JN.

J Natl Cancer Inst. 2015 Nov 27;108(5). pii: djv369. doi: 10.1093/jnci/djv369. Print 2016 May.

49.

Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases.

Vaidhyanathan S, Wilken-Resman B, Ma DJ, Parrish KE, Mittapalli RK, Carlson BL, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2016 Feb;356(2):251-9. doi: 10.1124/jpet.115.229393. Epub 2015 Nov 24.

50.

InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.

Ma Y, Tang N, Thompson RC, Mobley BC, Clark SW, Sarkaria JN, Wang J.

Clin Cancer Res. 2016 Apr 1;22(7):1767-76. doi: 10.1158/1078-0432.CCR-15-1677. Epub 2015 Nov 11.

Supplemental Content

Loading ...
Support Center